Vanda Pharmaceuticals Raises 2026 Revenue Guidance on Strong Q1 Sales & New Product Launches
VNDA sits 88% above its 52-week low of $3.809.
Summary
Vanda Pharmaceuticals reported Q1 2026 results, raising full-year revenue guidance to $240-$290 million driven by strong Fanapt sales and the launch of NEREUS™, alongside recent FDA approval for BYSANTI™.
Key Events · Earnings and Guidance · VNDA
-
Raised Full-Year 2026 Revenue Guidance
Vanda Pharmaceuticals increased its full-year 2026 total revenue guidance to $240-$290 million, up from the prior range of $230-$260 million, incorporating $10-$30 million from the newly launched NEREUS™.
-
Strong Q1 Product Sales & New Launch
Total net product sales for Q1 2026 reached $51.7 million, a 3% increase year-over-year, with Fanapt® sales growing 26% to $29.6 million. The company also commercially launched NEREUS™ (tradipitant) for motion-induced vomiting via a direct-to-consumer platform.
-
Key Regulatory Approvals & Pipeline Progress
BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in February 2026. The Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) was accepted for FDA review with a PDUFA target action date of December 12, 2026.
-
Increased Net Loss Amidst Investments
The company reported a net loss of $48.6 million ($0.82 diluted loss per share) in Q1 2026, compared to a net loss of $29.5 million in Q1 2025, reflecting continued investment in new product launches and pipeline advancement. Cash, cash equivalents, and marketable securities decreased by $61.5 million in Q1 2026 to $202.3 million.
Analysis · VNDA · Life Sciences
Vanda Pharmaceuticals reported a mixed first quarter, with a significantly increased net loss but also strong commercial execution and positive pipeline developments. The company raised its full-year 2026 revenue guidance to $240-$290 million, up from $230-$260 million, primarily driven by robust Fanapt sales growth and the successful launch of NEREUS™ (tradipitant) via a direct-to-consumer platform. Additionally, the FDA approval of BYSANTI™ (milsaperidone) in February and the BLA acceptance for imsidolimab for GPP with a PDUFA date in December 2026 highlight ongoing regulatory progress. While the net loss widened and cash decreased due to investments and a milestone payment, the raised guidance and new product commercialization efforts signal positive momentum and potential for future growth.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.8% of the 1152 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNDA was trading at $7.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $439.8M. The 52-week trading range was $3.81 to $9.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.